Search
Ferric oxide
go.drugbank.com/drugs/DB11576ApprovedInvestigationalIt is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.
Mixtures: Aveeno Calamine and Pramoxine Hydrochloride Anti ItchLevonordefrin
go.drugbank.com/drugs/DB06707ApprovedInvestigationalLevonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.
Mixtures: Mepivacaine Hydrochloride and LevonordefrinCategories: Epinephrine and similarsFludeoxyglucose (18F)
go.drugbank.com/drugs/DB09502ApprovedInvestigationalIt is administered by intravenous injection.
Categories: Indicators and ReagentsParomomycin
go.drugbank.com/drugs/DB01421ApprovedInvestigationalAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Categories: Alimentary Tract and MetabolismDanicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigationalParoxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction. … [A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system.[A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsSelexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Categories: Blood and Blood Forming OrgansMilsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. … [L56056] On February 20, 2026, milsaperidone was approved by the FDA for the treatment of Bipolar I Disorder and schizophrenia.[L56059]
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 … (pancreatitis and SIRS), and NCT04661540 (critical COVID-19 pneumonia).
Etofamide
go.drugbank.com/drugs/DB13258ApprovedEtofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].
Categories: Antiparasitic Products, Insecticides and RepellentsIcodextrin
go.drugbank.com/drugs/DB00702ApprovedInvestigationalIt is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. … Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers.